Rawalpindi Medical College, Pakistan Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00916461
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

National Coordinating Investigator, Rawalpindi Medical University, Pakistan | Rawalpindi Medical College

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Disease (Phase 3)

Mental Disorders (Phase 2)

Mood Disorders (Phase 3)

Psychotic Disorders (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 13